The stock of Cerus Corp. (NASDAQ:CERS) last traded at $1.97, down -3.43% from the previous session.
CERS stock price is now -4.57% away from the 50-day moving average and -0.45% away from the 200-day moving average. The market capitalization of the company currently stands at $357.12M.
On January 17, 2023, Stephens Downgraded its previous ‘Overweight’ rating to ‘Equal-Weight’ on the stock keeping its target price maintained at $3.75, while ‘BTIG Research’ rates the stock as ‘Buy’
In other news, Greenman William Mariner, President and CEO sold 63,611 shares of the company’s stock on Mar 14 ’24. The stock was sold for $128,195 at an average price of $2.02. Upon completion of the transaction, the President and CEO now directly owns 3,181,281 shares in the company, valued at $6.27 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 14 ’24, Chief Operating Officer Jayaraman Vivek K sold 26,794 shares of the business’s stock. A total of $52,902 was realized by selling the stock at an average price of $1.97. This leaves the insider owning 878,653 shares of the company worth $1.73 million. A total of 5.15% of the company’s stock is owned by insiders.
During the past 12 months, Cerus Corp. has had a low of $1.21 and a high of $3.08. As of last week, the company has a debt-to-equity ratio of 1.82, a current ratio of 2.14, and a quick ratio of 1.55. The fifty day moving average price for CERS is $2.0626 and a two-hundred day moving average price translates $1.9775 for the stock.
The latest earnings results from Cerus Corp. (NASDAQ: CERS) was released for Dec, 2023. According to the Medical Devices Company, earnings per share came in at -$0.01, beating analysts’ expectations of -$0.02 by 0.01. This compares to -$0.08 EPS in the same period last year. The net profit margin was -23.98% and return on equity was -62.35% for CERS. The company reported revenue of $53.34 million for the quarter, compared to $51.32 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3.94 percent. For the current quarter, analysts expect CERS to generate $42.08M in revenue.
Cerus Corp.(CERS) Company Profile
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
